Divi's Labs reported a 23 percent jump in net profit for the three months ended March at Rs 662 crore.

Divi's Labs' better-than-expected Q4 results trigger slew of price target upgrades

Despite brokerages raising price targets for Divi's Labs following its robust performance in Q4, they maintained neutral recommendations on the stock. Their rationale lies in the belief that the current stock valuations already the current stock valuations factor in much of its growth prospects.

Divi's Labs Q4 preview: Revenue, net profit to grow on normalised base, better product mix

The pharma company is expected to deliver decent earnings in Q4 FY24 aided by strong growth across its generics, nutraceuticals and custom synthesis businesses.

Divi's Labs Q2 Preview: Earnings likely to improve sequentially on better margins, product mix

A high base from the sales of COVID drug Molnupiravir and soft demand is likely to weigh the year-on-year growth for Divi's Labs

Divi's Labs Q1 Preview: Base effect to pressure earnings, brokerages predict sequential recovery

A high base due to strong COVID-sales contribution from Molnupiravir is expected to weigh on Q1 earnings for Divi's Labs.

Divi's Labs Preview: Unfavourable base, elevated input costs to turn Q4 a sour pill

Divi's Laboratories is likely to report a slump in its Q4 earnings on a year-on-year basis. However, sequentially, the drugmaker may see some modest recovery in its financials.

Divi’s Lab Q3FY23 preview: Consolidated net profit to likely drop 44% YoY

The company’s consolidated revenue will see a drop of 21% YoY, at Rs 1,980 crore. The YoY decline in sales is attributed to the slowing down of Molnupiravir sales as COVID cases fall.

Divi's Q1 Poll| Solid profit, revenue growth on cards, but costs could dent margin

Shares of Divi's have been under pressure this fiscal, as margin are weighed down by input cost, China lockdowns, and a spike in freight rates.

Divis Lab Q1 PAT seen up 27.3% YoY to Rs 709 cr: ICICI Direct

Net Sales are expected to increase by 18 percent Y-o-Y (down 8.1 percent Q-o-Q) to Rs 2,314.5 crore, according to ICICI Direct.

Divis Laboratories Q1 PAT seen up 12.5% YoY to Rs 626.8 cr: Prabhudas Lilladher

Net Sales are expected to increase by 12.9 percent Y-o-Y (down 12.1 percent Q-o-Q) to Rs 2,213 crore, according to Prabhudas Lilladher.

Divis Laboratories Q3 PAT seen up 42.7% YoY to Rs 671.7 cr: Prabhudas Lilladher

Net Sales are expected to increase by 28.4 percent Y-o-Y (up 9.9 percent Q-o-Q) to Rs 2,184 crore, according to Prabhudas Lilladher.

Divi’s Lab Q1 PAT seen up 8.4% YoY to Rs 533.6 cr: ICICI Direct

Net Sales are expected to increase by 8.9 percent Y-o-Y (up 5.4 percent Q-o-Q) to Rs 1,884 crore, according to ICICI Direct.

Divis Q4 PAT seen up 41.1% YoY to Rs. 467.2 cr: Sharekhan

Net Sales are expected to increase by 20.9 percent Y-o-Y (down 1.3 percent Q-o-Q) to Rs. 1,680 crore, according to Sharekhan.

Divi’s Q2 PAT may dip 9% YoY to Rs. 363.7 cr: Emkay

Net Sales are expected to increase by 5.4 percent Y-o-Y (up 16.5 percent Q-o-Q) to Rs. 1,354.7 crore, according to Emkay.

Divis Q3 PAT seen up 53.5% YoY to Rs. 370 cr: Sharekhan

Net Sales are expected to increase by 25 percent Y-o-Y (up 1 percent Q-o-Q) to Rs. 1,297.4 crore, according to Sharekhan.

Divi’s lab Q3 PAT seen up 82.3% YoY to Rs. 409.6 cr: ICICI Direct

Net Sales are expected to increase by 26.1 percent Y-o-Y (up 1.8 percent Q-o-Q) to Rs. 1,308.2 crore, according to ICICI Direct.

India Inc Q2 review: Earnings breadth deteriorates; margin pressure stark

Input cost pressure is being increasingly absorbed by companies as the demand environment in weakening

Divis Labs Q2 PAT seen up 45.7% YoY to Rs. 290 cr: HDFC Securities

Net Sales are expected to increase by 15 percent Y-o-Y (up 2.9 percent Q-o-Q) to Rs. 1,020 crore, according to HDFC Securities.

Divis Q2 PAT seen up 39.2% YoY to Rs. 272.5 cr: Sharekhan

Net Sales are expected to increase by 20 percent Y-o-Y (up 7.3 percent Q-o-Q) to Rs. 1,068.2 crore, according to Sharekhan.

Divi’s Lab Q2 PAT seen up 33% YoY to Rs. 275.1 cr: ICICI Direct

Net Sales are expected to increase by 13.7 percent Y-o-Y (up 1.7 percent Q-o-Q) to Rs. 1,012.4 crore, according to ICICI Direct.

Divi’s Lab Q4 PAT may dip 2.6% YoY to Rs. 280 cr: HDFC Securities

Net Sales are expected to increase by 6.7 percent Y-o-Y (up 9.6 percent Q-o-Q) to Rs. 1,140 crore, according to HDFC Securities.

Divis Labs Q2 profit seen down 1% on lower operational income and revenue

Revenue may decline due to ongoing USFDA import alert and re-inspection in Q2 of Unit 2.

Divis Q3 net likely up 11%, margins may be at 37%

Street will be squarely focused on commentary on 5 observations co received on its unit 2 by USFDA, inspected from Nov 29 to December 6. Analysts expect the observations to turn either into Warning letter or import alert. Unit 2 accounts for around 70 percent of company's revenue.

Divis Labs Q1 profit seen up 9%; revenue & EBITDA may jump 17%

Divis Laboratories' first quarter profit seen up 9 percent year-on-year to Rs 265.3 crore and revenue may jump 17 percent to Rs 948 crore, according to a CNBC-TV18 poll.

Divis Labs Q1 PAT seen down by 19.5% at Rs 259.3 cr: Religare

Sales are expected to decrease by 13.7 percent Q-o-Q (up 16.9 percent Y-o-Y) to Rs 945.1 crore, according to Religare Research.